GLP1R and Venous thrombosis: GLP-1 analogs were associated with lower risk of all arterial thrombosis (HR, 0.74, [95% CI: 0.67, 0.81]; p < 0.0001) and venous thrombosis (HR, 0.80 [95% CI: 0.68, 0.93]; p = 0.004), as well as an overall decreased all-cause mortality (HR 0.56 [95% CI: 0.50, 0.62]; p < 0.0001) (Table 2).